October 29, 2001 16:12Pall and QIAGEN in Alliance to Develop and Market Nucleic Acid Handling and Purification Consumable ProductsQIAGEN Soon to Market Jointly Developed Products to Fast-Growing Life Science Market EAST HILLS, N.Y. and VENLO, Netherlands, Oct. 29 /PRNewswire/ -- Pall Corporation (NYSE: PLL) and QIAGEN N.V. (Nasdaq: QGENF, Frankfurt, Neuer Markt: QIA, Easdaq: QGEN) today announced that they have entered into an agreement to jointly develop next-generation nucleic acid separation and purification products for certain applications in the life science market. The jointly developed products will exclusively be marketed by QIAGEN. This agreement puts Pall, the global leader in the highly sophisticated and broad filtration, separations and purification industry into an alliance with QIAGEN, the highly focused worldwide technology and market leader in the area of nucleic acid separation and purification products for the rapidly expanding life science market. The first suite of products intended for near-term launch will focus on products combining certain of Pall's filtration technologies with certain of QIAGEN's technologies for applications in medium-, high-, and ultra-high throughput separation and purification of certain types of nucleic acids widely analyzed in genomics applications. The parties believe that these intended products which will also be optimized for use on QIAGEN's leading automation solutions will allow QIAGEN to further increase its expanding leadership in these market segments. In addition, the Companies have also entered into a long-term supply agreement for certain of Pall's existing consumable products that QIAGEN expects to market to its customers once slight modifications to those products are completed. Financial terms were not disclosed. "Pall's expertise in development of separations media and devices for the life sciences industry, combined with QIAGEN's leading nucleic acid separation and purification technologies forge a strong basis for a powerful alliance. Nucleic acid separation, purification and handling is believed to be an over $800 million market and possibly one of the fastest growing applications for separations technologies within the life science industry. We are very pleased to have been chosen by QIAGEN, the innovative global market and technology leader in this market as a partner," said Eric Krasnoff, Chairman and Chief Executive Officer of Pall Corporation. Pall's filtration, separation and purification technologies accelerate the process of drug discovery and development and ensure drugs are produced to the highest standards. Pall is the only company whose portfolio of filtration, purification and separations technologies spans the full spectrum of life sciences applications from the earliest stages of research through production and delivery of new drugs and diagnostics for patient care. As part of the Company's Life Sciences mission, it is actively developing partnerships with companies, such as QIAGEN, that provide complementary technologies and that can thereby translate Pall's technologies into powerful product offerings for such partners' core markets. QIAGEN believes that certain of Pall's many separations technologies have potential applicability for nucleic acid separation and purification solutions. Dr. Metin Colpan, Chief Executive Officer of QIAGEN added, "We are very pleased to be working with Pall on what we believe to be an exciting combination of Pall's broad and deep portfolio in separation technologies and media with QIAGEN's leadership and expertise in applying such technologies in nucleic acid separation and purification. QIAGEN has a history of expertise in modifying and enhancing separation and purification technologies directed and applied in other markets and integrating such technologies with technologies from QIAGEN's broad proprietary technology portfolio to create exciting nucleic acid separation and purification solutions for our customers. We have long admired Pall's fascinating breadth of technologies for purification of the most diverse substances in many different markets -- from water filtration to technologies for separations used in drug manufacturing. We believe that certain of Pall's technologies have the potential to show exciting applicability in nucleic acid separation and purification. " About Pall Corporation Pall Corporation is the leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in blood banking and transfusion medicine, biotechnology, pharmaceuticals, semiconductors, municipal drinking water and aerospace. Fiscal 2001 sales were over $1.2 billion. The Company is headquartered in East Hills, New York and has major operations in more than 30 countries. Further information is available at http://www.pall.com. About QIAGEN N.V. QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,500 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com. Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of each of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC). CONTACTS: Peer M. Schatz Diane Foster Chief Financial Officer Investor Relations QIAGEN N.V. Pall Corporation +49 (0)2103 29 11702 +1 (516) 484 3600 x 6109 e-mail: p.schatz@de.QIAGEN.com e-mail: firstname.lastname@example.org Dr. Solveigh Mahler Noonan Russo Communications Manager Investor Relations Veronica Sellar QIAGEN N.V. +44 (0)20 7726 4452 +49 (0)2103 29 11710 Mary Claire Duch e-mail: s.maehler@de.QIAGEN.com +1 (212) 696 4455 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X14731863SOURCE Pall Corporation and QIAGEN N.V. -0- 10/29/2001 /CONTACT: Peer M. Schatz, Chief Financial Officer of QIAGEN N.V., +49 -0-2103-29-11702, p.schatz@de.QIAGEN.com; or Dr. Solveigh Mahler, Manager Investor Relations of QIAGEN N.V., +49 -0-2103-29-11710, s.maehler@de.QIAGEN.com; or Diane Foster, Investor Relations of Pall Corporation, +1-516-484-3600, ext. 6109, email@example.com; or Noonan Russo Communications - Veronica Sellar, +44 / /Web site: http://www.qiagen.com http://www.pall.com / (QGENF PLL)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat